Kucera Katerina S, Taylor Jennifer L, Robles Veronica R, Clinard Kristin, Migliore Brooke, Boyea Beth Lincoln, Okoniewski Katherine C, Duparc Martin, Rehder Catherine W, Shone Scott M, Fan Zheng, Raspa Melissa, Peay Holly L, Wheeler Anne C, Powell Cynthia M, Bailey Donald B, Gehtland Lisa M
RTI International, Research Triangle Park, Durham, NC 27709, USA.
American College of Medical Genetics and Genomics, Bethesda, MD 20814, USA.
Int J Neonatal Screen. 2021 Mar 21;7(1):20. doi: 10.3390/ijns7010020.
Prior to statewide newborn screening (NBS) for spinal muscular atrophy (SMA) in North Carolina, U.S.A., we offered voluntary screening through the Early Check (EC) research study. Here, we describe the EC experience from October 2018 through December 2020. We enrolled a total of 12,065 newborns and identified one newborn with 0 copies of and two copies of , consistent with severe early onset of SMA. We also detected one false positive result, likely stemming from an unrelated blood disorder associated with a low white blood cell count. We evaluated the timing of NBS for babies enrolled prenatally ( = 932) and postnatally ( = 11,133) and reasons for delays in screening and reporting. Although prenatal enrollment led to faster return of results (median = 13 days after birth), results for babies enrolled postnatally were still available within a timeframe (median = 21 days after birth) that allowed the opportunity to receive essential treatment early in life. We evaluated an SMA q-PCR screening method at two separate time points, confirming the robustness of the assay. The pilot project provided important information about SMA screening in anticipation of forthcoming statewide expansion as part of regular NBS.
在美国北卡罗来纳州开展全州范围的脊髓性肌萎缩症(SMA)新生儿筛查(NBS)之前,我们通过早期检查(EC)研究开展了自愿筛查。在此,我们描述2018年10月至2020年12月期间的EC筛查情况。我们共招募了12,065名新生儿,发现1名新生儿为SMN1基因0拷贝且SMN2基因2拷贝,符合SMA严重早发型。我们还检测到1例假阳性结果,可能源于与白细胞计数低相关的一种无关血液疾病。我们评估了产前(n = 932)和产后(n = 11,133)登记入组婴儿的NBS时间以及筛查和报告延迟的原因。尽管产前登记入组导致结果返回更快(出生后中位数 = 13天),但产后登记入组婴儿的结果仍能在一个时间范围内获得(出生后中位数 = 21天),这使得有机会在生命早期接受必要治疗。我们在两个不同时间点评估了一种SMA定量聚合酶链反应(q-PCR)筛查方法,证实了该检测方法的稳健性。该试点项目为即将作为常规NBS一部分在全州范围内扩大SMA筛查提供了重要信息。